Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2018. Start Trial.
Date Value
September 30, 2026 0.5365M
June 30, 2026 0.9081M
March 31, 2026 1.524M
December 31, 2025 1.910M
September 30, 2025 3.469M
June 30, 2025 6.278M
March 31, 2025 9.907M
December 31, 2024 13.33M
September 30, 2024 15.37M
June 30, 2024 15.45M
March 31, 2024 13.96M
December 31, 2023 12.38M
September 30, 2023 10.80M
June 30, 2023 11.41M
March 31, 2023 12.19M
December 31, 2022 13.38M
September 30, 2022 14.35M
June 30, 2022 13.94M
Date Value
March 31, 2022 13.97M
December 31, 2021 14.51M
September 30, 2021 14.68M
June 30, 2021 14.58M
March 31, 2021 13.88M
December 31, 2020 13.26M
September 30, 2020 13.24M
June 30, 2020 13.08M
March 31, 2020 13.73M
December 31, 2019 14.10M
September 30, 2019 14.90M
June 30, 2019 14.18M
March 31, 2019 13.02M
December 31, 2018 11.10M
September 30, 2018 8.655M
June 30, 2018 7.076M
March 31, 2018 5.651M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
EyePoint, Inc. 296.65M
ANI Pharmaceuticals, Inc. 50.60M
Corcept Therapeutics, Inc. 241.72M
Veru, Inc. 11.76M
Johnson & Johnson 16.02B